CORRECTING AND REPLACING -- Agile Therapeutics
April 20 2021 - 10:56AM
In a release issued earlier today by Agile Therapeutics, Inc.
(Nasdaq: AGRX), please note the headline should read "Agile
Therapeutics to Report First Quarter 2021 Financial Results and
Provide Business Update on Tuesday, May 4, 2021" instead of "Agile
Therapeutics to Report First Quarter 2021 Financial Results and
Provide Business Update on Tuesday, May 4, 2020". The corrected
release follows:
Agile Therapeutics to Report First Quarter 2021 Financial
Results and Provide Business Update on Tuesday, May 4, 2021
Live Conference Call and Webcast at 4:30 p.m.
EDT
Agile Therapeutics, Inc. (Nasdaq: AGRX), a
women’s healthcare company, today announced it will report first
quarter 2021 financial results after the market close
on Tuesday, May 4, 2021 as follows:
Date |
Tuesday, May 4, 2021 |
Time |
4:30 p.m. EDT |
Webcast (live and
archived) |
Events &
Presentations |
Dial-in numbers |
(866) 324-3683 (U.S.
toll-free) or (509) 844-0959 |
Conference ID |
2334548 |
Investors interested in listening to the conference call may do
so by dialing (866) 324-3683 for domestic callers or (509) 844-0959
for international callers. A live webcast will be available in the
Events and Presentations section of the Investor Relations page at
https://ir.agiletherapeutics.com/events-and-presentations/, or by
clicking here.
Please log in approximately 10 minutes prior to the scheduled
start time. The archived webcast will be available in the Events
and Presentations section of the company's website.
About Agile Therapeutics, Inc.Agile
Therapeutics is a forward-looking women's healthcare company
dedicated to fulfilling the unmet health needs of today’s
women. Our product and product candidates are designed to
provide women with contraceptive options that offer freedom from
taking a daily pill, without committing to a longer-acting
method. Our initial product, Twirla®, (levonorgestrel and
ethinyl estradiol), a transdermal system, is a non-daily
prescription contraceptive. Twirla is based on our proprietary
transdermal patch technology, called Skinfusion®, which is designed
to allow drug delivery through the skin. For more information,
please visit the company website
at www.agiletherapeutics.com. The Company may
occasionally disseminate material, nonpublic information on the
Company’s website.
Contact: Matt RileyHead of Investor
Relations & Corporate
Communicationsmriley@agiletherapeutics.com
Agile Therapeutics (NASDAQ:AGRX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Agile Therapeutics (NASDAQ:AGRX)
Historical Stock Chart
From Apr 2023 to Apr 2024